ovarian cancer
Conditions
Interventions
Case series:Apatinib combined with conventional chemotherapy regimen
Sponsors
Yibin second people's Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. female aged 18 to 70 years old; 2. According to the RECIST 1.1 criteria, the patient has at least one target lesion that can measure the diameter; 3. Patients with epithelial ovarian cancer who received first-line chemotherapy treatment (6 months after treatment or 6 months after completion of treatment) were diagnosed with epithelial ovarian cancer with clear imaging diagnosis as progression of disease. Persistent and refractory ovarian cancer patients. 4. ECOG score: 0-2 points; 5. more than the expected survival time in March; 6. the main organs function properly, that is, the following standards: (1) routine blood test standards should be consistent (within 14 days without blood transfusion and blood products, not using G-CSF and other hematopoietic stimulating factors to correct): HB=90 g/L; ANC= 1.5 * 10^9/L; PLT = 80 * 10^9/L; (2) biochemical examination should meet the following standards: TBIL 45 ml/min (Cockcroft-Gault formula); 7. Participants volunteered to join the study and signed informed consent, good compliance and follow up.
Exclusion criteria
Exclusion criteria: 1. Patients with hypertension who are unable to fall below the normal range after treatment with antihypertensive drugs (systolic> 140 mmHg, diastolic> 90 mmHg); 2. With previous serious cardiovascular disease: myocardial ischemia or myocardial infarction grade ? or above, poorly controlled arrhythmia (including QTc interval men = 450 ms, women = 470 ms); according to the NYHA standard, III ~ IV Cardiac insufficiency, or cardiac ultrasonography revealed left ventricular ejection fraction (LVEF) 1.0g); 4. Patients with bleeding predisposition or those with an event of anastomotic / venous thrombosis within 12 months with coagulation abnormalities (INR> 1.5, APTT> 1.5 ULN) 5. Patients who have history of psychotropic substance abuse who can not be abstinent or who have mental disorders 6. At the investigator's discretion, there are other serious patients who may endanger the patient's safety or affect the patient's companion disease that completed the study; 7. Researchers think it is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;DCR; | — |
Countries
China
Contacts
Public ContactWang Shanbin
Yibin second people's Hospital
Outcome results
None listed